Format

Send to

Choose Destination
See comment in PubMed Commons below
Bioengineered. 2013 May-Jun;4(3):153-7. doi: 10.4161/bioe.22676. Epub 2012 Oct 30.

Recombinant snake venom prothrombin activators.

Author information

1
AstraZeneca R&D Bioscience, Mölndal, Sweden. ann.lovgren@astrazeneca.com

Abstract

Three prothrombin activators; ecarin, which was originally isolated from the venom of the saw-scaled viper Echis carinatus, trocarin from the rough-scaled snake Tropidechis carinatus, and oscutarin from the Taipan snake Oxyuranus scutellatus, were expressed in mammalian cells with the purpose to obtain recombinant prothrombin activators that could be used to convert prothrombin to thrombin. We have previously reported that recombinant ecarin can efficiently generate thrombin without the need for additional cofactors, but does not discriminate non-carboxylated prothrombin from biologically active γ-carboxylated prothrombin. Here we report that recombinant trocarin and oscutarin could not efficiently generate thrombin without additional protein co-factors. We confirm that both trocarin and oscutarin are similar to human coagulation Factor X (FX), explaining the need for additional cofactors. Sequencing of a genomic fragment containing 7 out of the 8 exons coding for oscutarin further confirmed the similarity to human FX.

KEYWORDS:

FX; coagulation Factor X; prothrombin activator; recombinant ecarin; recombinant oscutarin; recombinant trocarin; thrombin

PMID:
23111318
PMCID:
PMC3669156
DOI:
10.4161/bioe.22676
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center